Nearly 200 deaths and over 150,000 adverse reactions have been linked to anti-obesity drugs Mounjaro, Wegovy, Ozempic, and Saxenda in the UK, according to data from the MHRA Yellow Card scheme.
Vivani Medical is developing a GLP-1 implant for long-term weight loss maintenance, potentially reducing side effects and injection fatigue. The device, an experimental semaglutide implant, aims for twice-yearly or annual administration, complementing existing GLP-1 treatments. However, it faces clinical trials, regulatory hurdles, and questions about cost and physician adoption.
Dr Reddy's Laboratories will halt semaglutide injection supplies until at least October due to unspecified impurities found during API manufacturing scale-up. Marketed products are safe, but Torrent Pharma and USV are recalling some batches sourced from DRL.
Dr Reddy's Laboratories announced a delay in commercial supplies of its semaglutide products due to out-of-specification batches linked to an active pharmaceutical ingredient (API) issue. The company is investigating the root cause and implementing corrective measures, assuring no impact on patient safety or global filings.
The once-a-day Wegovy weight-loss pill, containing semaglutide, is now available in UK high street and online pharmacies for private prescription. It is not yet available on the NHS. The pill offers a needle-free alternative to the jab but requires specific administration on an empty stomach.
The UK's MHRA has approved the first GLP-1 receptor agonist tablet, semaglutide (Wegovy), for weight loss and management. This daily pill offers a more convenient alternative to weekly injections for adults with obesity or those overweight with weight-related conditions.
A study by the University of California, San Diego, suggests semaglutide, a drug for weight loss and diabetes, may slow biological aging. Participants taking semaglutide showed a 9% reduction in aging rate and improved health markers compared to a placebo group.
Alkem Laboratories launched semaglutide in single-shot pre-filled syringes in India, making diabetes and obesity treatment more accessible and affordable. The company is the first in India to offer this format, intensifying competition in the growing drug market.
A UK study suggests Semaglutide may benefit patients unresponsive to bariatric surgery. Separately, oats are highlighted for their role in managing blood sugar for diabetics due to soluble fiber. Additionally, experts warn that processed foods, refined carbs, and high sodium/saturated fat diets can exacerbate stress hormone (cortisol) levels.
Scientists found that semaglutide and colchicine protect heart tissue from inflammation and electrical signaling disturbances that can cause arrhythmias. Semaglutide notably reduces scar tissue in the atria and maintains normal electrical impulse transmission.
Prices for generic semaglutide, a weight-loss drug, may drop by over 50% in 6-8 months due to new market entrants and reduced API costs, potentially reaching ₹500/month.
Dr Reddy's Laboratories has become the first company to receive Health Canada approval for generic semaglutide injection, covering 2 mg/pen and 4 mg/pen dosages. The approval, granted ahead of the regulatory review target date, marks a significant milestone in the company's GLP-1 journey and aims to expand access to affordable diabetes treatments for Canadian patients, where approximately 3.9 million people (9.7% of the population) live with diagnosed diabetes.
Dr Reddy's Laboratories has received notice of compliance from Health Canada for its generic semaglutide injection, becoming the first company to receive market authorization for this diabetes treatment in Canada. The approval covers 2 mg/pen and 4 mg/pen dosages. The company is preparing to launch the medication to provide Canadian patients with access to this therapy.
